Wesbanco Bank Inc. Makes New $895,000 Investment in Bioventus Inc. $BVS

Wesbanco Bank Inc. purchased a new position in shares of Bioventus Inc. (NASDAQ:BVS) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 98,000 shares of the company’s stock, valued at approximately $895,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Nantahala Capital Management LLC boosted its stake in shares of Bioventus by 4.1% during the 4th quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock worth $44,993,000 after acquiring an additional 236,741 shares in the last quarter. Vanguard Group Inc. raised its holdings in Bioventus by 4.4% during the third quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock worth $19,567,000 after purchasing an additional 122,749 shares during the last quarter. Royce & Associates LP boosted its position in Bioventus by 15.6% during the third quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock worth $8,449,000 after purchasing an additional 170,900 shares in the last quarter. Geode Capital Management LLC boosted its position in Bioventus by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after purchasing an additional 19,388 shares in the last quarter. Finally, State Street Corp boosted its position in Bioventus by 1.7% during the fourth quarter. State Street Corp now owns 891,024 shares of the company’s stock worth $6,629,000 after purchasing an additional 14,590 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BVS. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. CJS Securities began coverage on shares of Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective on the stock. Barrington Research reissued an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a research note on Friday, May 22nd. Craig Hallum lifted their target price on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Finally, Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $14.20.

Bioventus Stock Performance

Bioventus stock opened at $9.78 on Monday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The stock has a fifty day moving average of $9.55 and a two-hundred day moving average of $8.75. The company has a market capitalization of $816.97 million, a price-to-earnings ratio of 23.85, a PEG ratio of 1.26 and a beta of 0.67. Bioventus Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $11.25.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The business had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, analysts anticipate that Bioventus Inc. will post 0.77 EPS for the current fiscal year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.